-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-518991-30-00
6
2025-07-17
kidney cancer
-
2024-517423-40-00
5
2025-06-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-514560-10-00
4
2025-06-12
Patients with newly diagnosed advanced peritoneal metastasis from colo
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-517921-14-00
9
2025-05-07
Neuroendocrine tumors of midgut origin
-
2024-510893-25-00
5
2025-04-29
Brain metastases of cancer > brain radionecrosis
-
2024-512043-22-00
4
2025-04-11
Metastatic prostate cancer
-
2024-512729-10-00
4
2025-03-27
Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
-
2023-503326-39-00
5
2025-03-06
Synchronous oligometastatic non-small cell lung cancer (NSCLC)
-
2023-505291-30-01
4
2025-03-06
Triple Negative Breast Cancer with residual disease after neoadjuvant
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2023-509963-25-00
4
2025-01-17
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
-
2024-512161-14-00
3
2025-01-14
Breast Cancer
-
2023-509811-98-00
4
2025-01-07
Patients with HER2-positive locally advanced inoperable or metastatic
-
2023-506350-21-00
4
2025-01-06
Localized, resected, FIGO stage I (2018 classification), uterine leiom
-
2024-513081-19-00
4
2024-12-24
high-grade cervical intraepithelial lesions
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2024-511313-38-00
4
2024-11-17
Soft Tissue Sarcoma
-
2023-509230-19-00
7
2024-11-14
Advance solid tumors